Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.82 |
| ▸ | TDO2 | P48775 | 16/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16247490 | 0.90 | IDO1 (1.00) | IDO1TDO2 | |
| SCHEMBL16247583 | 0.86 | TDO2 (0.76) | IDO1TDO2 | |
| SCHEMBL16247478 | 0.85 | TDO2 (0.74) | IDO1TDO2 | |
| SCHEMBL16238387 | 0.85 | TDO2 (1.00) | IDO1TDO2 | |
| SCHEMBL16247536 | 0.85 | IDO1 (0.66) | IDO1TDO2 | |
| SCHEMBL16247475 | 0.84 | TDO2 (1.00) | IDO1TDO2 | |
| SCHEMBL16247516 | 0.84 | TDO2 (1.00) | IDO1TDO2 | |
| SCHEMBL16247374 | 0.83 | TDO2 (0.74) | IDO1TDO2 | |
| SCHEMBL16247404 | 0.83 | TDO2 (0.71) | IDO1TDO2 | |
| SCHEMBL16247381 | 0.83 | TDO2 (0.71) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294212-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2019-05-21 | — | — | US | claimed |
| EP-2970173-B1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD (IN) | 2018-05-09 | — | — | EP | claimed |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PVT LTD | 2018-02-01 | — | — | US | claimed |
| US-9815811-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2017-11-14 | — | — | US | claimed |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2016-02-18 | — | — | US | claimed |
| EP-2970173-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | Curadev Pharma Private Ltd. (IN) | 2016-01-20 | — | — | EP | claimed |
| WO-2014186035-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2014-11-20 | — | — | WO | claimed |
| US-10294212-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2019-05-21 | — | — | US | disclosed |
| US-10294212-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2019-05-21 | — | — | US | disclosed |
| EP-2970173-B1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD (IN) | 2018-05-09 | — | — | EP | disclosed |
| EP-2970173-B1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD (IN) | 2018-05-09 | — | — | EP | disclosed |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PVT LTD | 2018-02-01 | — | — | US | disclosed |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PVT LTD | 2018-02-01 | — | — | US | disclosed |
| US-9815811-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2017-11-14 | — | — | US | disclosed |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| EP-2970173-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | Curadev Pharma Private Ltd. (IN) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014186035-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014186035-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294212-B2 | Inhibitors of the kynurenine pathway | IDO1, IDO2, KYNU | IDO1 1/4885TDO2 6/4885 |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | IDO1, IDO2, KYNU | IDO1 1/4885TDO2 6/4885 |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | IDO1, KYNU, IDO2 | IDO1 1/4885TDO2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.